vast
major
billion
dose
vaccin
manufactur
worldwid
year
given
perfectli
healthi
peopl
fact
drive
requir
vaccin
among
rigor
design
monitor
compliant
product
manufactur
today
abil
manufactur
vaccin
safe
consist
built
four
compet
manufactur
process
defin
product
made
complianc
organ
success
complet
process
test
product
support
oper
regulatori
author
releas
distribut
product
chapter
examin
compon
establish
develop
new
vaccin
field
vaccin
manufactur
respond
emerg
challeng
increas
capac
eg
pandem
influenza
increas
safeti
assur
eg
barrier
isol
fill
increas
complex
manufactur
eg
conjug
vaccin
must
accomplish
consist
deliv
billion
dose
annual
rel
low
cost
similar
therapeut
product
unit
state
vaccin
regul
biolog
product
food
drug
administr
fda
center
biolog
evalu
research
cber
respons
regul
vaccin
unit
state
current
author
regul
vaccin
resid
primarili
section
public
health
servic
act
specif
section
feder
food
drug
cosmet
act
section
public
health
servic
act
give
feder
govern
author
licens
biolog
product
establish
produc
vaccin
undergo
rigor
review
laboratori
nonclin
clinic
data
ensur
safeti
efficaci
puriti
potenc
vaccin
approv
market
may
also
requir
undergo
addit
studi
evalu
vaccin
often
address
specif
question
vaccin
safeti
effect
possibl
side
effect
european
union
anim
human
vaccin
regul
european
medicin
agenc
ema
whose
main
respons
promot
public
anim
health
ema
committe
medicin
product
human
use
vaccin
work
parti
oversight
human
vaccin
vaccin
licens
central
procedur
allow
simultan
licensur
within
countri
within
european
union
human
vaccin
manufactur
regul
good
manufactur
practic
gmp
direct
annex
annex
harmon
licens
regul
procedur
vaccin
worldwid
obviou
benefit
rapidli
deliv
safe
effect
vaccin
market
impedi
harmon
includ
lack
standard
regulatori
procedur
mutual
recognit
licens
inspect
countri
worldwid
regulatori
agenc
harmon
regul
continu
progress
joint
fdaema
establish
inspect
program
becom
realiti
adher
harmon
intern
confer
harmonis
ich
guidanc
expect
new
vaccin
subject
welldefin
regulatori
process
approv
approv
process
consist
four
princip
element
prepar
preclin
materi
proofofconcept
test
anim
model
manufactur
clinic
materi
accord
current
gmp
cgmp
toxicolog
analysi
appropri
anim
system
submiss
investig
new
drug
applic
ind
submiss
fda
review
test
safeti
effect
clinic
nonclin
studi
phase
clinic
studi
submiss
clinic
nonclin
manufactur
data
fda
ema
form
biolog
licens
applic
bla
final
review
licensur
chapter
outlin
basic
manufactur
vaccin
descript
exampl
current
licens
product
move
regulatori
requir
vaccin
manufactur
includ
cgmp
complianc
discuss
develop
new
vaccin
final
section
examin
great
challeng
field
deliv
product
held
everincreas
standard
safeti
provid
suffici
dose
reason
cost
everincreas
number
diseas
manufactur
vaccin
compos
sever
basic
step
result
finish
product
summari
step
exampl
pathogen
licens
vaccin
given
tabl
first
step
gener
antigen
use
induc
immun
respons
step
includ
gener
pathogen
subsequ
inactiv
isol
subunit
gener
recombin
protein
deriv
pathogen
vaccin
develop
use
addit
method
discuss
later
virus
grown
cell
primari
cell
chicken
fibroblast
yellow
fever
grown
continu
cell
line
viral
bacteri
seed
cultur
cell
line
use
viral
product
care
control
store
character
often
protect
first
step
manufactur
establish
master
cell
bank
collect
vial
cell
form
start
materi
futur
product
extens
character
perform
absenc
adventiti
agent
bank
work
cell
bank
prepar
use
routin
start
cultur
product
lot
final
vaccin
direct
function
start
materi
chang
seed
complic
initi
new
product
develop
altogeth
next
step
releas
antigen
substrat
isol
bulk
environ
use
growth
isol
free
viru
secret
protein
cell
cell
contain
antigen
spent
medium
next
step
purif
antigen
vaccin
compos
recombin
protein
step
may
involv
mani
unit
oper
column
chromatographi
ultrafiltr
inactiv
viral
vaccin
may
simpli
inactiv
isol
viru
purif
formul
vaccin
design
maxim
stabil
vaccin
deliv
format
allow
effici
distribut
prefer
clinic
deliveri
product
formul
vaccin
may
includ
adjuv
enhanc
immun
respons
stabil
prolong
shelf
life
andor
preserv
allow
multidos
vial
deliv
formul
consist
combin
compon
constitut
final
vaccin
uniformli
mix
singl
vessel
figur
oper
conduct
highli
control
environ
employe
wear
special
protect
cloth
avoid
adventiti
contamin
critic
work
area
control
monitor
environ
critic
surfac
conduct
oper
qualiti
control
qc
test
stage
usual
consist
safeti
potenc
puriti
steril
assay
specif
product
phase
individu
scrupul
clean
depyrogen
singl
multipledos
contain
fill
vaccin
seal
steril
stopper
plunger
vaccin
lyophil
vial
stopper
insert
partial
allow
moistur
escap
lyophil
process
vial
move
lyophil
chamber
vial
receiv
outer
cap
stopper
secur
preclud
introduct
extran
viabl
nonviabl
contamin
fill
oper
must
take
place
highli
control
environ
peopl
equip
compon
introduc
critic
area
control
manner
fill
contain
inspect
use
semiautom
autom
equip
design
detect
minut
cosmet
physic
defect
formul
phase
vaccin
manufactur
oper
extens
control
monitor
environ
critic
surfac
conduct
oper
qc
test
stage
also
consist
safeti
potenc
puriti
steril
assay
may
specif
product
vaccin
efficaci
advers
affect
improp
distribut
storag
condit
sensit
vaccin
advers
environment
condit
particularli
temperatur
extrem
vari
depend
composit
live
attenu
vaccin
tend
suscept
kill
vaccin
toxoid
addit
stabil
lyophil
feasibl
tend
improv
thermal
resist
vaccin
although
recommend
storag
condit
mani
vaccin
detail
vaccin
manufactur
respons
develop
data
licens
demonstr
stabil
vaccin
recommend
storag
condit
claim
shelf
life
gener
program
provid
data
excess
claim
shelf
life
year
support
develop
new
product
intend
clinic
use
routin
support
current
market
product
expir
date
extens
support
distribut
condit
acceler
studi
conduct
elev
temperatur
commonli
appli
better
understand
impact
transient
temperatur
excurs
vaccin
manufactur
requir
assur
product
control
maintain
appropri
condit
ident
strength
qualiti
puriti
product
affect
current
limit
number
vaccin
requir
feder
regul
specifi
ship
temperatur
although
vaccin
manufactur
use
insul
contain
precaut
brief
usual
hour
ship
time
occasion
unanticip
temperatur
excurs
may
occur
could
detriment
impact
ship
product
accept
vaccin
shipment
user
look
evid
improp
transport
condit
includ
excess
transport
time
possibl
advers
ambient
temperatur
condit
influenza
viru
vaccin
usp
intramuscular
use
steril
suspens
prepar
influenza
virus
propag
chicken
embryo
vaccin
primari
method
prevent
influenza
sever
complic
vaccin
contain
two
strain
influenza
virus
singl
influenza
b
viru
addit
strain
influenza
b
viru
recent
ad
first
four
antigen
contain
vaccin
licens
two
type
virus
identifi
subtyp
hemagglutinin
ha
neuraminidas
na
ha
na
glycoprotein
influenza
viru
compris
major
surfac
protein
princip
immun
antigen
viru
protein
insert
viral
envelop
spikelin
project
ratio
trival
subunit
vaccin
predomin
influenza
vaccin
use
today
vaccin
produc
viral
strain
identifi
earli
year
world
health
organ
center
diseas
control
prevent
cdc
cber
uslicens
manufactur
viral
strain
normal
acquir
cber
cdc
european
strain
typic
provid
nation
institut
biolog
standard
control
southern
hemispher
strain
therapeut
good
administr
australia
viral
strain
use
prepar
inoculum
vaccin
product
substrat
commonli
use
produc
influenza
vaccin
embryon
chicken
egg
monoval
viru
suspens
receiv
cber
cdc
monoval
viru
suspens
pass
egg
inocul
egg
incub
specif
time
temperatur
regimen
control
rel
humid
harvest
harvest
allanto
fluid
contain
live
viru
test
infect
titer
specif
steril
fluid
store
wet
frozen
extrem
low
temperatur
maintain
stabil
monoval
seed
viru
msv
msv
also
certifi
cber
msv
introduc
egg
autom
inocul
viru
grown
incub
temperatur
allanto
fluid
harvest
purifi
highspe
centrifug
sucros
gradient
chromatographi
purifi
viru
often
split
use
deterg
final
filtrat
viru
inactiv
use
formaldehyd
primari
purif
step
depend
manufactur
repeat
three
strain
viru
individu
test
releas
inactiv
viral
concentr
combin
dilut
final
vaccin
strength
overal
process
outlin
figur
juli
recombin
hepat
b
vaccin
licens
unit
state
vaccin
built
knowledg
heatinactiv
serum
contain
hepat
b
viru
hbv
hepat
b
surfac
antigen
hbsag
infecti
immunogen
partial
protect
subsequ
exposur
hbv
determin
hbsag
compon
confer
protect
hbv
immun
produc
vaccin
hbsag
gene
insert
express
vector
capabl
direct
synthesi
larg
quantiti
hbsag
saccharomyc
cerevisia
hbsag
particl
express
purifi
yeast
cell
demonstr
equival
hbsag
deriv
plasma
blood
hepat
b
chronic
carrier
recombin
cerevisia
cell
express
hbsag
grown
stir
tank
ferment
medium
use
process
complex
ferment
medium
consist
extract
yeast
soy
pepton
dextros
amino
acid
miner
salt
inprocess
test
conduct
ferment
product
determin
percentag
host
cell
express
construct
end
ferment
process
hbsag
harvest
lyse
yeast
cell
separ
hydrophob
interact
sizeexclus
chromatographi
result
hbsag
assembl
lipoprotein
particl
hbsag
purifi
greater
protein
seri
physic
chemic
method
purifi
protein
treat
phosphat
buffer
formaldehyd
steril
filter
coprecipit
alum
potassium
aluminum
sulfat
form
bulk
vaccin
adjuv
amorph
aluminum
hydroxyphosph
sulfat
vaccin
contain
detect
yeast
dna
may
contain
yeast
protein
second
recombin
hepat
b
vaccin
surfac
antigen
express
cerevisia
cell
purifi
sever
physiochem
step
formul
suspens
antigen
absorb
aluminum
hydroxid
procedur
use
manufactur
result
product
contain
yeast
protein
substanc
human
origin
use
manufactur
vaccin
hepat
b
prepar
recombin
yeast
cultur
noninfecti
free
associ
human
blood
blood
product
lot
hepat
b
vaccin
test
safeti
mice
guinea
pig
steril
qc
product
test
puriti
ident
includ
numer
chemic
biochem
physic
assay
final
product
assur
thorough
character
lottolot
consist
quantit
immunoassay
use
monoclon
antibodi
use
measur
presenc
high
level
key
epitop
yeastderiv
hbsag
mous
potenc
assay
also
use
measur
immunogen
hepat
b
vaccin
effect
dose
capabl
seroconvert
mice
ed
calcul
hepat
b
vaccin
steril
suspens
intramuscular
inject
vaccin
suppli
four
formul
pediatr
adolescenthighrisk
infant
adult
dialysi
formul
contain
approxim
mg
aluminum
provid
amorph
aluminum
hydroxyphosph
sulfat
per
millilit
vaccin
qc
test
requir
releas
recombin
hepat
b
vaccin
summar
tabl
vaccin
still
releas
cber
lotbylot
basi
sever
extens
character
vaccin
requir
elimin
includ
hepat
b
vaccin
human
papillomaviru
hpv
vaccin
manufactur
use
recombin
dna
process
manufactur
process
includ
signific
purif
extens
character
analyt
method
addit
hepat
b
vaccin
demonstr
track
record
continu
safeti
puriti
potenc
qualifi
exempt
product
haemophilu
type
b
conjug
includ
separ
product
capsular
polysaccharid
haemophilu
influenza
type
b
carrier
protein
tetanu
protein
clostridium
tetani
ie
purifi
tetanu
toxoid
crm
protein
corynebacterium
diphtheria
outer
membran
protein
complex
neisseria
meningitidi
capsular
polysaccharid
produc
industri
bioreactor
use
approv
seed
h
influenza
type
b
crude
intermedi
recov
ferment
supernat
use
cation
deterg
result
materi
harvest
continuousflow
centrifug
past
resuspend
buffer
polysaccharid
select
dissoci
disrupt
past
increas
ionic
strength
polysaccharid
purifi
phenol
extract
ultrafiltr
ethanol
precipit
final
materi
precipit
alcohol
dri
vacuum
store
process
tetanu
protein
prepar
bioreactor
use
approv
seed
c
tetani
crude
toxin
recov
cultur
supernat
continuousflow
centrifug
diafiltr
crude
toxin
purifi
combin
fraction
ammonium
sulfat
precipit
ultrafiltr
result
purifi
toxin
detoxifi
use
formaldehyd
concentr
ultrafiltr
store
process
industri
conjug
process
initi
develop
use
tetanu
toxoid
jb
robbin
team
nation
institut
allergi
infecti
diseas
niaid
bethesda
maryland
conjug
prepar
twostep
process
involv
activ
hib
capsular
polysaccharid
conjug
activ
polysaccharid
tetanu
protein
spacer
activ
includ
chemic
fragment
nativ
polysaccharid
specifi
molecular
weight
target
coval
linkag
adip
acid
dihydrazid
activ
polysaccharid
coval
link
purifi
tetanu
protein
carbodiimidemedi
condens
use
carbodiimid
purif
conjug
materi
perform
obtain
highmolecularweight
conjug
molecul
devoid
chemic
residu
free
protein
polysaccharid
conjug
bulk
dilut
appropri
buffer
fill
unitdos
andor
multidos
vial
lyophil
measl
viru
isol
part
genu
morbilliviru
famili
paramyxovirida
current
vaccin
deriv
edmonston
moraten
schwarz
strain
vaccin
market
sinc
combin
mmr
sinc
final
vaccin
live
attenu
viral
vaccin
induc
immun
recipi
manufactur
measl
start
specif
pathogenfre
spf
embryon
chicken
egg
incub
sever
day
embryo
collect
treat
trypsin
prepar
chick
embryo
fibroblast
cell
cultur
oper
done
strict
asept
condit
perform
welltrain
oper
cell
cultur
grown
roller
bottl
use
fetal
calf
sera
hank
media
optim
cell
growth
chick
embryo
fibroblast
cell
infect
viral
work
seed
incub
sever
day
viral
cultur
end
viral
cultur
cell
disrupt
mechan
lysi
releas
viru
viru
purifi
centrifug
filtrat
store
frozen
releas
qc
test
vaccin
formul
alon
mump
rubella
vaccin
lyophil
obtain
stabl
product
vaccin
reconstitut
use
tradit
viral
vaccin
reli
attenu
viru
strain
inactiv
infecti
viru
subunit
vaccin
base
viral
protein
express
heterolog
system
effect
pathogen
often
poor
immunogen
due
incorrect
fold
modif
viruslik
particl
vlp
design
mimic
overal
structur
viru
particl
thu
preserv
nativ
antigen
conform
immunogen
protein
vlp
produc
wide
rang
taxonom
structur
distinct
virus
uniqu
potenti
advantag
term
safeti
immunogen
previou
approach
attenu
inactiv
vlp
requir
particularli
import
epitop
commonli
modifi
inactiv
treatment
howev
viral
vector
eg
baculoviru
use
express
system
inactiv
may
requir
purif
process
elimin
residu
viral
activ
vlp
realist
vaccin
candid
need
produc
safe
express
system
easi
scale
largescal
product
accompani
purif
inactiv
process
maintain
nativ
structur
immunogen
meet
requir
today
global
regulatori
author
number
express
system
demonstr
manufactur
multimer
vlp
includ
baculoviru
express
system
bve
high
five
cell
escherichia
coli
aspergillu
niger
chines
hamster
ovari
human
function
liver
cell
babi
hamster
kidney
transgen
plant
potato
tobacco
soybean
cerevisia
pichia
pastori
human
embryon
kidney
lupin
callu
yield
rang
high
e
coli
purifi
mani
pathogen
virus
influenza
hiv
hepat
c
surround
envelop
membran
consist
lipid
bilay
deriv
host
cell
insert
viru
glycoprotein
spike
protein
target
neutral
antibodi
essenti
compon
vaccin
owe
inher
properti
lipid
envelop
assembl
vlp
insect
cell
virus
differ
type
technic
challeng
produc
virus
multipl
capsid
target
product
vlp
challeng
task
synthesi
assembl
one
recombin
protein
may
requir
case
vlp
rotaviru
rlp
rna
viru
capsid
form
monom
four
differ
protein
addit
product
vlp
requir
simultan
express
assembl
sever
recombin
protein
case
rlp
need
occur
singl
host
cell
purif
vlp
also
constitut
particularli
challeng
task
vlp
structur
sever
nanomet
diamet
molecular
weight
rang
da
also
guarante
qualiti
product
suffici
demonstr
absenc
contamin
protein
also
necessari
show
protein
correctli
assembl
vlp
hpv
type
major
capsid
protein
produc
certain
recombin
express
system
cerevisia
form
irregularli
shape
vlp
broad
size
distribut
hpv
vlp
inher
unstabl
tend
aggreg
solut
primari
challeng
hpv
vaccin
formul
develop
prepar
aqueou
hpv
vlp
solut
stabl
varieti
purif
process
storag
condit
treat
hpv
vlp
process
disassembl
reassembl
stabil
vitro
potenc
vaccin
enhanc
significantli
addit
vivo
immunogen
vaccin
also
improv
much
approxim
shown
mous
potenc
studi
disassembl
reassembl
particl
may
also
import
remov
residu
protein
express
systemhost
cell
use
product
seriou
process
challeng
particularli
envelop
vlp
vaccin
develop
involv
process
take
new
antigen
immunogen
identifi
research
process
develop
substanc
final
vaccin
evalu
preclin
clinic
studi
determin
safeti
efficaci
result
vaccin
process
product
compon
inprocess
materi
final
product
specif
manufactur
process
defin
manufactur
scale
use
develop
usual
significantli
smaller
use
final
manufactur
process
phase
sometim
phase
clinic
trial
vaccin
typic
produc
product
develop
usual
anticip
least
one
three
consist
lot
use
phase
clinic
trial
manufactur
fullscal
product
volum
product
manufactur
develop
phase
manufactur
accord
cgmp
histor
us
manufactur
bound
cgmp
detail
section
section
us
code
feder
regul
cfr
appli
specif
approv
drug
biolog
product
feder
regul
set
forth
detail
cgmp
provid
principl
method
ensur
product
meet
safeti
requir
manufactur
process
consist
produc
product
meet
specifi
ident
strength
qualiti
puriti
specif
set
forth
licens
vaccin
product
domest
intern
drug
biolog
manufactur
saw
rapid
increas
law
regul
guidelin
report
evalu
data
safeti
qualiti
efficaci
new
product
industri
time
becom
intern
seek
new
global
market
registr
vaccin
remain
nation
respons
although
differ
regulatori
system
base
fundament
oblig
evalu
qualiti
safeti
efficaci
detail
technic
requir
diverg
extent
industri
found
necessari
duplic
mani
timeconsum
expens
test
procedur
market
new
product
intern
need
harmon
regul
also
fuel
concern
rise
cost
health
care
escal
cost
research
develop
public
expect
minimum
delay
make
safe
efficaci
new
treatment
avail
patient
end
intern
confer
harmon
ich
born
committe
includ
regulatori
scientif
represent
unit
state
europ
asia
provid
regulatori
scientif
guidanc
requir
manufactur
pharmaceut
biolog
guidelin
requir
take
place
codifi
us
cgmp
howev
manufactur
appli
ich
guidanc
default
complianc
us
cgmp
intern
cgmp
requir
harmon
current
licens
new
vaccin
specif
test
requir
remain
challeng
industri
regulatori
author
applic
cgmp
materi
produc
human
clinic
trial
codifi
well
defin
domest
intern
regul
although
specif
note
current
cfr
introduct
cgmp
includ
preambl
state
cgmp
requir
applic
investig
materi
intend
manufactur
appli
cgmp
applic
practic
take
account
intent
clinic
trial
phase
manufactur
process
develop
applic
cgmp
summar
initi
ind
subsequ
supplement
build
manufactur
control
assur
safeti
efficaci
product
european
union
issu
direct
emea
specif
manufactur
investig
materi
though
lack
specif
detail
applic
cgmp
provid
focu
qualiti
investig
suppli
direct
gone
far
requir
inspect
certif
manufactur
prepar
investig
materi
intend
use
european
clinic
trial
clinic
materi
produc
phase
clinic
trial
use
demonstr
candid
product
safeti
rel
small
number
healthi
human
patient
ten
volunt
verifi
abil
manufactur
product
duplic
theoret
process
use
manufactur
preclin
materi
use
anim
toxicolog
studi
applic
appropri
written
control
accur
consist
data
record
control
equip
prepar
test
even
earlystag
candid
vaccin
materi
critic
ensur
desir
outcom
set
foundat
subsequ
develop
potenti
candid
vaccin
expect
phase
cgmp
applic
includ
follow
personnel
adequ
educ
experi
train
perform
function
includ
cgmp
train
written
qualiti
unit
respons
appropri
train
disposit
compon
procedur
assay
batch
investig
deviat
adequ
design
facil
util
includ
hvac
design
minim
contamin
appropri
water
sourc
qualiti
basic
procedur
control
prevent
contamin
mixup
appropri
equip
intend
function
properli
design
maintain
calibr
oper
per
written
instruct
appropri
qualif
control
assur
safeti
product
eg
viral
clearanc
toxin
inactiv
written
compon
raw
materi
control
includ
establish
accept
criteria
appropri
disposit
traceabl
written
product
record
procedur
includ
record
compon
equip
chang
procedur
process
microbi
control
record
appropri
asept
process
perform
adequ
condit
train
personnel
written
test
procedur
perform
control
condit
use
scientif
sound
analyt
methodolog
specifi
accept
criteria
laboratori
instrument
oper
per
written
procedur
maintain
calibr
qualifi
safeti
test
eg
steril
endotoxin
packag
protect
product
contamin
control
label
oper
design
prevent
mixup
adequ
document
storag
ship
control
ensur
integr
product
phase
clinic
trial
intend
demonstr
safeti
dose
respons
larger
target
popul
would
expect
receiv
vaccin
hundr
volunt
manufactur
phase
clinic
trial
materi
use
develop
initi
consist
product
manufactur
incorpor
modif
improv
base
phase
product
test
experi
identif
key
candid
process
control
point
monitor
trend
evalu
equip
materi
assur
applic
gmp
conform
consid
stage
phase
clinic
trial
intend
demonstr
safeti
efficaci
statist
signific
target
popul
ten
thousand
volunt
demonstr
abil
consist
manufactur
materi
meet
predescrib
qualiti
attribut
modif
improv
base
phase
product
test
experi
incorpor
manufactur
process
specif
process
control
point
defin
process
system
necessari
manufactur
test
latestag
clinic
materi
valid
accord
cgmp
essenti
mimick
requir
appli
approv
product
riskbas
approach
cgmp
applic
consist
phase
develop
provid
assur
evid
product
safeti
assur
desir
target
molecul
deriv
process
control
minimum
includ
follow
remov
potenti
variabl
surround
manufactur
process
valid
monitor
potenti
contributor
environ
util
equip
valid
finish
product
safeti
test
includ
gener
safeti
steril
endotoxin
ensur
process
design
capabl
remov
undesir
contamin
process
stream
valid
test
per
process
step
comprehens
document
manufactur
test
experi
cgmp
detail
section
section
cfr
analyt
test
vaccin
provid
evid
vaccin
intermedi
meet
specif
defin
within
bla
safeti
efficaci
potenc
test
associ
licens
vaccin
maintain
within
approv
file
publish
cfr
part
addit
usp
prepar
monograph
approv
vaccin
provid
standard
requir
continu
add
monograph
new
vaccin
proceed
commerci
bulk
vaccin
must
test
safeti
efficaci
manufactur
cber
releas
final
formul
packag
cber
develop
concept
wellcharacter
biolog
defin
chemic
entiti
whose
ident
puriti
impur
potenc
quantiti
determin
control
analyt
test
control
manufactur
process
advantag
wellcharacter
product
quantifi
analyt
measur
relat
molecul
structur
function
applic
definit
allow
manufactur
biolog
elimin
need
cber
releas
biolog
distribut
market
also
allow
process
chang
take
place
product
licens
current
analyt
process
technolog
allow
applic
definit
recombin
dna
protein
monoclon
antibodi
product
howev
except
one
current
licens
vaccin
vaccin
gener
meet
criteria
wellcharacter
owe
complex
size
structur
inabl
fulli
character
quantifi
analyt
biolog
paramet
recent
vaccin
develop
focus
molecul
meet
criteria
wellcharacter
product
chemic
microbi
physic
assay
vaccin
develop
concurr
product
process
develop
process
step
output
test
use
varieti
analyt
techniqu
design
understand
character
structur
target
molecul
associ
impur
mani
test
use
process
valid
activ
demonstr
capabl
robust
process
ident
test
biolog
includ
wide
varieti
test
design
specif
moieti
base
uniqu
characterist
molecular
structur
properti
ident
test
may
includ
one
mani
complementari
test
includ
physicochem
biolog
immunolog
assay
ident
test
tradit
use
rel
simpl
test
advanc
analyt
technolog
provid
better
specif
multival
combin
vaccin
becom
critic
ensur
compon
adequ
distinguish
one
exampl
advanc
technolog
replac
multipl
colorimetr
assay
singl
nmr
spectral
analysi
multival
polysaccharid
identif
current
method
list
tabl
puriti
test
develop
identifi
potenti
processor
productrel
impur
may
trace
process
equip
inher
product
impur
test
may
includ
chromatograph
method
allow
quantit
trace
amount
impur
raw
materi
processrel
impur
chromatograph
resin
leakag
inher
copurifi
protein
contamin
detect
use
electrophoresi
techniqu
quantifi
trace
amount
proteinac
contamin
detect
residu
dna
tradit
use
spectral
analysi
quantit
although
advanc
polymeras
chain
reaction
pcr
assay
allow
even
greater
sensit
exampl
current
method
list
tabl
microbi
test
includ
bioburden
steril
endotoxin
adventiti
viral
mycoplasma
agent
test
also
develop
base
process
capabl
control
contamin
microorgan
inher
process
impur
vaccin
larg
molecul
depend
biochem
makeup
physic
configur
provid
desir
immunolog
respons
unlik
small
molecul
steam
steril
vaccin
prepar
asept
steril
test
use
bulk
vaccin
final
dosag
form
still
provid
limit
assur
steril
sampl
bulk
finish
product
lot
test
current
advanc
steril
bioburden
test
includ
use
process
analysi
technolog
rapid
micro
test
sensit
one
bacteri
cell
per
sampl
current
valid
implement
reduc
current
steril
test
time
day
hour
tradit
endotoxin
pyrogen
test
perform
use
anim
respons
assess
pyrogen
compound
relianc
endotoxin
limulu
amebocyt
lysat
lal
test
assess
pyrogen
becom
standard
test
new
vaccin
current
test
tradit
perform
accord
point
consid
ich
guidanc
regard
adventiti
agent
test
includ
viral
test
mycoplasma
test
advanc
technolog
also
involv
pcr
detect
presenc
contamin
adventiti
agent
process
final
formul
addit
pyrogen
test
gener
safeti
test
abnorm
toxic
test
perform
test
requir
vaccin
productspecif
safeti
test
perform
laboratori
anim
inject
mice
guinea
pig
assess
anim
distress
current
altern
abnorm
toxic
test
exampl
specif
safeti
test
anim
use
ensur
effect
inactiv
exotoxin
produc
host
bacteri
cell
advanc
replac
anim
test
includ
use
vero
cell
assay
extrem
sensit
toxin
assay
measur
enzymat
activ
toxin
also
biochem
assay
use
fluoresc
peptid
mimick
natur
substrat
develop
tetanu
pertussi
toxin
live
viru
vaccin
also
use
safeti
test
assur
virus
revert
wild
virul
type
mani
anim
model
use
assess
viral
vaccin
safeti
advanc
pcr
technolog
provid
sensit
altern
assess
mutat
genom
viru
quantit
test
perform
determin
content
mass
target
activ
moieti
vaccin
formul
physiochem
procedur
detect
chang
molecul
time
tradit
test
includ
colorimetr
spectrophotometr
assay
gener
precis
sensit
detect
chang
target
molecul
separ
assay
highperform
liquid
chromatographi
capillari
electrophoresi
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
indic
stabil
lack
product
degrad
proteinbas
vaccin
routin
includ
total
protein
test
antigen
provid
quantit
measur
antigen
present
measur
antigenantibodi
interact
antigen
assay
fall
four
group
radioimmunoassay
enzym
immunoassay
nonlabel
immunoassay
biosensor
analysi
potenc
test
use
assur
vaccin
produc
desir
immunolog
effect
per
specif
potenc
test
fall
one
four
categori
tradit
animalbas
assay
measur
biolog
respons
anim
model
cell
culturebas
assay
measur
biochem
physiolog
respons
cellular
level
biolog
activ
respons
induc
immunolog
interact
ligand
receptor
bind
assay
base
vivo
attribut
activ
molecul
cell
culturebas
enzymelink
immunosorb
assay
test
use
known
antibodyantigen
interact
continu
replac
accentu
classic
animalbas
model
desir
potenc
assay
provid
abil
detect
chang
activ
molecul
time
challeng
vaccin
manufactur
develop
appropri
correl
chemic
biolog
approach
replac
current
anim
model
use
correspond
assay
physic
chemic
test
perform
final
formul
dosag
form
character
materi
test
includ
ph
quantit
preserv
quantit
adjuv
uniform
particul
matter
loss
dri
residu
moistur
dissolut
lyophil
final
dosag
form
subset
releas
test
provid
assess
stabil
ensur
vaccin
continu
meet
product
specif
time
new
technolog
manufactur
test
describ
earlier
current
licens
vaccin
manufactur
live
attenu
inactiv
purifi
subunit
conjug
recombin
protein
antigen
recent
introduct
conjug
vaccin
introduc
greater
complex
suppli
chain
mani
compon
must
manufactur
separ
conjug
purifi
formul
singl
vaccin
current
trend
field
aim
enhanc
suppli
chain
robust
cell
culturederiv
flu
vaccin
develop
abil
manufactur
new
type
vaccin
plasmid
dna
viral
vector
peptid
live
bacteria
irradi
sporozoit
current
licens
flu
vaccin
made
embryon
chicken
egg
process
requir
extrem
larg
quantiti
pathogenfre
egg
manufactur
process
new
technolog
develop
use
continu
cell
line
product
influenza
viru
vaccin
varieti
cell
line
current
develop
promis
provid
robust
system
manufactur
bulk
influenza
vaccin
cell
line
develop
includ
vero
process
elimin
risk
avian
influenza
viru
could
infect
flock
produc
egg
current
vaccin
manufactur
infect
would
potenti
elimin
suppli
vaccin
entir
number
cell
culturederiv
influenza
vaccin
approv
europ
although
scale
capabl
provid
suffici
vaccin
replac
eggderiv
vaccin
respond
pandem
event
strong
industri
academ
govern
focu
recent
year
promis
advanc
develop
technolog
manufactur
develop
process
produc
influenza
vaccin
use
cell
cultur
use
bioreactor
similar
l
model
figur
vaccin
pilot
plant
vaccin
research
center
niaid
nation
institut
health
contrari
popular
belief
reduct
product
cycl
time
batch
vaccin
made
cell
cultur
compar
use
embryon
egg
although
avail
latter
problem
pandem
event
furthermor
limit
factor
time
suppli
vaccin
capac
perform
releas
test
steril
filtrat
steril
fill
vaccin
sever
vaccin
develop
use
plasmid
dna
deliveri
vehicl
known
genet
vaccin
protein
antigen
deliv
dna
sequenc
taken
host
express
vivo
particularli
provid
advantag
viral
vaccin
host
express
protein
may
provid
protein
nativ
conform
thu
better
immun
respons
manufactur
plasmid
dna
vaccin
done
e
coli
grown
larg
bioreactor
varieti
downstream
process
unit
oper
isol
plasmid
dna
e
coli
lysi
chemic
heat
follow
solid
remov
chromatograph
select
precipit
plasmid
must
separ
genom
dna
host
cell
protein
host
cell
rna
endotoxin
although
plasmid
product
rel
high
human
clinic
studi
prophylact
vaccin
use
dose
mg
plasmid
dna
make
potenti
manufactur
signific
econom
engin
challeng
anoth
genet
immun
strategi
use
virus
deliv
genet
sequenc
pathogen
protein
viral
vector
includ
recombin
adenovirus
poxvirus
alphavirus
vector
develop
replicationincompet
like
mani
adenovir
vector
vector
contain
delet
nativ
virus
render
replicationincompet
safeti
reason
delet
also
allow
insert
gene
interest
vector
vector
replic
requir
complementari
cell
line
call
packag
cell
line
provid
miss
genet
inform
replic
vector
expand
packag
cell
line
vector
must
purifi
separ
host
cell
protein
dna
rna
vector
like
poxviru
vector
replicationcompet
grown
permiss
cell
line
without
requir
genet
modif
product
techniqu
usual
includ
cell
lysi
chromatographi
ultrafiltr
isol
purifi
vector
one
novel
vaccin
product
technolog
recent
propos
product
irradi
plasmodium
falciparum
sporozoit
mosquito
malaria
p
falciparum
pathogen
respons
malaria
report
vaccin
contain
irradi
sporozoit
convey
efficaci
current
estim
enough
irradi
sporozoit
could
harvest
singl
mosquito
immun
singl
human
one
compani
sanaria
explor
whether
suffici
quantiti
could
grown
mosquito
harvest
consist
qualiti
manner
would
allow
licensur
type
vaccin
initi
clinic
test
show
suboptim
immunogen
protect
given
intraven
although
certainli
unconvent
fact
malaria
current
caus
approxim
million
clinic
case
million
death
year
warrant
develop
one
recent
major
shift
industri
around
concern
avian
influenza
pandem
prepar
strong
respons
reduc
impact
pandem
pandem
would
trigger
combin
avian
influenza
strain
human
strain
mutat
avian
strain
allow
infect
spread
human
popul
human
natur
immun
avian
strain
even
healthi
adult
expect
background
antibodi
level
fight
infect
event
could
trigger
global
epidem
take
million
live
also
take
major
toll
global
econom
first
line
defens
possibl
pandem
govern
vaccin
manufactur
team
secur
suppli
chain
influenza
vaccin
prepar
clinic
test
avian
influenza
vaccin
circul
avian
strain
stockpil
vaccin
circul
avian
strain
expand
manufactur
distribut
infrastructur
prepar
deliveri
vaccin
addit
fear
thought
pandem
bring
everyon
tri
understand
pandem
trigger
mani
new
issu
vaccin
manufactur
previou
threat
pandem
influenza
eg
swine
flu
border
countri
close
transport
vaccin
leav
countri
without
manufactur
infrastructur
also
without
vaccin
least
initi
respons
manufactur
abl
produc
global
suppli
singl
locat
border
block
capitalintens
region
approach
ie
multipl
small
plant
would
requir
product
influenza
vaccin
requir
mani
compon
outsid
manufactur
plant
compon
suppli
chainegg
vial
stopper
reagent
labor
prepar
deliv
compon
manufacturerar
risk
pandem
vendor
support
vaccin
manufactur
need
protect
priorit
one
might
expect
major
disrupt
suppli
good
pandem
event
firm
could
close
restrict
oper
owe
risk
ill
absente
noncrit
worker
may
restrict
oper
site
critic
workforc
sequest
protect
spread
diseas
support
product
vaccin
fight
diseas
appli
vaccin
manufactur
also
industri
agenc
support
today
vaccin
still
made
embryon
chicken
egg
tradit
influenza
vaccin
made
januari
juli
chicken
replac
year
maintain
product
egg
qualiti
pandem
start
time
chicken
produc
egg
vaccin
respons
would
rather
slow
manufactur
establish
yearround
egg
suppli
allow
strong
instant
respons
pandem
point
year
unit
state
depart
health
human
servic
support
fund
conting
suppli
also
avian
strain
abnorm
bird
market
unit
state
threat
human
infect
new
protect
flock
diseas
alway
concern
focu
manufactur
vendor
support
biosecur
measur
place
sinc
major
avian
outbreak
destroy
major
eggproduc
flock
establish
us
manufactur
measur
secur
suppli
egg
ever
sinc
regardless
conting
suppli
ad
secur
product
quantiti
egg
even
chicken
flock
lost
avian
influenza
outbreak
avian
influenza
would
requir
termin
interpandem
product
annual
flu
vaccin
year
excess
capac
exist
even
support
today
grow
influenza
vaccin
need
even
routin
annual
vaccin
peopl
hospit
annual
due
influenza
number
expect
increas
significantli
without
annual
vaccin
howev
lack
inher
protect
avian
strain
make
vaccin
still
import
routin
influenza
vaccin
current
target
vaccin
respons
unit
state
prepar
million
dose
monoval
avian
flu
vaccin
within
month
approxim
million
trival
dose
influenza
vaccin
avail
us
flu
season
react
urgent
manner
facil
built
expand
global
support
larger
faster
respons
vaccin
control
pandem
outbreak
ideal
situat
one
interpandem
product
influenza
vaccin
interrupt
pandem
event
bottleneck
product
pandem
event
expect
suppli
vaccin
concentr
need
fill
finish
larg
quantiti
short
time
also
overlook
meet
million
dose
target
month
million
dose
need
fill
day
addit
product
continu
suppli
maintain
vaccin
diseas
suppli
supplier
fill
compon
could
impact
pandem
event
absente
expect
high
critic
suppli
could
risk
transport
industri
expect
signific
impact
case
pandem
vaccin
distribut
aspect
suppli
taken
grant
ad
consider
scarciti
vaccin
earli
respons
period
increas
need
secur
shipment
loss
due
temperatur
excurs
interrupt
shipment
theft
overal
plan
prepar
pandem
event
allencompass
exercis
everi
part
vaccin
busi
support
agenc
cooper
assist
govern
global
benefit
parti
benefit
consum
end
mani
countri
long
domest
vaccin
product
capabl
countri
like
china
india
brazil
south
korea
recent
develop
new
stateofth
art
manufactur
capabl
introduct
novel
vaccin
domest
popul
export
vaccin
intern
market
expans
emerg
market
manufactur
driven
sever
key
enabl
first
establish
central
fund
procur
distribut
vaccin
emerg
market
organ
allow
manufactur
work
singlepoint
contact
procur
coordin
distribut
vaccin
market
serv
exampl
organ
pan
american
health
organ
procur
vaccin
much
central
south
america
gavi
allianc
formerli
call
global
allianc
vaccin
immun
elimin
need
establish
separ
suppli
chain
sale
channel
divers
market
vaccin
export
emerg
market
use
world
health
organ
qualif
process
process
establish
examin
qualiti
vaccin
manufactur
process
separ
evalu
technic
commerci
abil
organ
manufactur
vaccin
process
provid
standard
regulatori
framework
enabl
manufactur
gain
approv
recogn
mani
emerg
market
replac
need
gain
regulatori
approv
individu
countri
global
transit
manufactur
mani
industri
product
lower
cost
geograph
region
also
evid
vaccin
global
manufactur
like
glaxosmithklin
sanofi
pasteur
merck
establish
joint
ventur
made
acquisit
india
china
brazil
ventur
case
howev
run
challeng
multin
firm
sanofi
exampl
acquir
shanta
biotechn
shanta
indiabas
vaccin
manufactur
suppli
vaccin
prequalif
program
soon
acquisit
howev
shanta
cite
qualiti
problem
lost
prequalif
statu
one
vaccin
substanti
interest
develop
past
decad
use
vaccin
elicit
bodi
immun
system
treat
diseas
onset
target
diseas
caus
infecti
agent
cancer
autoimmun
current
effort
devot
develop
therapeut
vaccin
tumor
aid
hepat
b
tuberculosi
malaria
autoimmun
diseas
myasthenia
gravi
system
lupu
erythematosu
rheumatoid
arthriti
fda
approv
first
therapeut
cancer
vaccin
sipuleucelt
proveng
develop
manufactur
dendreon
vaccin
approv
use
men
metastat
prostat
cancer
whose
tumor
longer
respond
hormon
therapi
demonstr
provid
median
improv
overal
surviv
compar
placebo
vaccin
approv
valid
concept
activ
treatment
approach
immunotherapi
intend
train
immun
system
attack
cancer
cell
potenti
get
respons
longlast
effect
though
cure
vaccin
provid
signific
clinic
benefit
sipuleucelt
custom
patient
treatment
patient
undergo
procedur
call
leukapheresi
isol
antigenpres
cell
apc
blood
apc
includ
dendrit
cell
macrophag
among
cell
present
marker
antigen
surfac
recogn
immun
cell
therebi
spark
immun
respons
apc
cultur
proprietari
manufactur
protein
end
result
vaccin
hundr
million
activ
apc
load
antigen
commonli
found
prostat
cancer
cell
call
prostat
acid
phosphatas
pap
vaccin
return
patient
treat
physician
infus
patient
intent
spur
immun
system
cell
cell
neutral
tumor
cell
express
pap
histor
vaccin
manufactur
dedic
facil
ensur
segreg
product
product
develop
sophist
engin
control
air
handl
autom
clean
analyt
test
residu
product
result
fda
guidelin
use
pilot
manufactur
facil
multiproduct
launch
biolog
result
tremend
amount
innov
technolog
enabl
rapid
convers
facil
one
product
anoth
typic
cell
would
grown
bioreactor
made
stainless
steel
shown
figur
use
reactor
extens
clean
test
ensur
clean
adequ
newer
technolog
use
plastic
bag
use
discard
exampl
system
shown
figur
use
singleus
technolog
allow
faster
changeov
one
batch
anoth
one
product
anoth
reduc
clean
steril
valid
recent
report
shown
substanti
save
cost
lead
time
new
facil
reduct
overal
oper
expens
use
new
technolog
elimin
preserv
extens
increas
vaccin
puriti
specif
issu
relat
public
percept
vaccin
safeti
exampl
preserv
use
vaccin
formul
includ
thimeros
deriv
mercuri
phenol
benzethonium
formaldehyd
benzethonium
often
mix
formaldehyd
improv
effect
broader
spectrum
potenti
contamin
compound
bactericid
andor
bacteriostat
properti
preserv
necessari
improv
safeti
vaccin
histor
abil
make
steril
product
manufactur
formul
fill
process
legaci
manufactur
process
facil
challeng
imposs
without
preserv
furthermor
preserv
requir
multidos
contain
prevent
contamin
futur
dose
extract
first
dose
vial
risk
infect
sepsi
due
dose
contamin
unpreserv
vial
consid
far
greater
risk
advers
event
preserv
elimin
preserv
facil
process
use
manufactur
vaccin
overhaul
case
preserv
use
inactiv
agent
integr
manufactur
process
fulli
remov
case
level
significantli
reduc
diafiltr
fulli
elimin
signific
impact
elimin
preserv
consequenti
switch
multidos
vial
singledos
present
impact
threefold
decreas
product
capac
increas
product
consumpt
per
unit
higher
consumpt
storag
space
manufactur
distributor
physician
offic
largest
initi
impact
manufactur
remov
preserv
greater
number
unit
need
fill
exampl
sanofi
pasteur
typic
fill
million
dose
flu
vaccin
week
vial
singl
fill
line
million
unit
dose
need
fill
inspect
packag
period
elimin
preserv
influenza
vaccin
million
unit
would
need
fill
time
exist
fill
line
manufactur
site
combin
capabl
fill
number
vial
andor
syring
time
requir
meet
need
influenza
vaccin
demand
larg
invest
new
line
necessari
make
switch
unitdos
present
chang
singl
dose
alreadi
underway
product
capac
alreadi
consum
effort
necessari
produc
high
volum
vaccin
satisfi
health
need
increas
likewis
fill
challeng
everi
vial
syring
also
need
inspect
product
containerclosur
defect
packag
insert
carton
store
await
regulatori
releas
ship
custom
entir
suppli
chain
product
expand
pend
chang
great
benefit
multidos
product
present
manufactur
consum
save
product
fill
imposs
get
content
singl
dose
vial
syring
administr
therefor
manufactur
need
fill
extra
product
never
administ
aid
practition
deliv
intend
dose
call
overfil
overfil
vial
ml
fill
volum
dose
practition
claim
abil
get
dose
vial
singl
dose
put
vial
higher
overfil
need
ensur
full
withdraw
dose
unitdos
vial
overfil
ml
per
vial
dose
convers
product
multidos
vial
unitdos
vial
result
addit
loss
product
owe
overfil
therefor
sanofi
pasteur
state
capac
million
dose
flu
vaccin
reduc
million
dose
chang
alon
chang
recogn
rush
remov
preserv
acellular
pertussi
vaccin
result
nationwid
shortag
dtap
vaccin
manufactur
time
increas
capac
switch
altern
present
less
overfil
unitdos
unpreserv
product
prefil
syring
fill
volum
prefil
syring
vari
design
fill
volum
commerci
avail
design
low
ml
equal
lower
millilit
per
dose
consumpt
rang
vial
syring
complic
handl
fill
line
also
carri
higher
perunit
cost
materi
save
bulk
make
chang
posit
manufactur
limit
total
bulk
capac
us
vaccin
market
larg
vial
market
product
success
move
syring
unit
state
unpreserv
present
develop
includ
tetanusdiphtheria
vaccin
decavac
howev
total
syring
fill
capac
limit
major
expans
underway
global
ad
syring
fill
capac
support
industri
neg
impact
convers
product
unitdos
present
one
space
storag
capac
manufactur
distributor
practition
need
expand
packag
unitdos
vial
two
time
larger
vial
likewis
space
requir
syring
time
vial
industri
develop
compact
packag
design
minim
impact
chang
consum
invest
new
packag
equip
larg
urgent
issu
preserv
remov
great
cascad
impact
manufactur
suppli
vaccin
consum
great
deal
technic
engin
effort
capit
invest
resolv
deliv
exist
product
consum
new
form
true
ad
benefit
consum
may
difficult
measur
ad
cost
complex
consum
obviou
